Adjuvant therapy of resected non-small-cell lung cancer

Current Opinion in Oncology

Volumn 12, Issue 2, 2000, Pages 149-155

  Keller, Steven M ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; MITOMYCIN; NAVELBINE; UFT; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; REVIEW; THORACOTOMY;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; PATIENT CARE PLANNING; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 0034509439     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200003000-00009     Document Type: Review

References (23)

1. Effect of surgical removal of the growth and kinetics of residual tumor
2. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases
3. Revision in the international system for staging lung cancer
4. Regional lymph node classification for lung cancer staging
5. Intraoperative assessment of nodal staging at thoracotomy for carcinoma of the bronchus
6. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer
7. Chemotherapy in non-small cell lung cancer a meta-analysis using updated data on individual patients from 52 randomized clinical trials
8. Discrepancies between meta-analyses and subsequent large randomized, controlled trials
9. The promise and problems of meta-analysis
10. Adjuvant therapy of non-small cell lung cancer
11. Postoperative radiotherapy in non-small-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials
12. Radiotherapy vs follow up in the treatment of non small cell lung cancer (NSCLC) P-staged 1a and 1b. Early stopped analysis of a randomized controlled study
13. Postoperative radiotherapy (XRT) for non-small cell lung carcinoma (NSCLC) doses not lead to excess rate of intercurrent death
14. The impact of surgical adjuvant thoracic radiation for different stages on non-small cell lung cancer: The experience from a single institution
15. Patterns of recurrence and outcome for patients with clinical stage II non-small-cell lung cancer
16. Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer
17. UFT and leucovorin: A review of its clinical development and therapeutic potential in the oral treatment of cancer
18. Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)
19. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegafur) in resected stage I-II NSCLC (non-small cell lung cancer): A randomized trial
20. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An intergroup trial (E3590)
21. A phase I/II trial of UFT and low-dose cisplatin plus concurrent thoracic radiotherapy (TRT) for resected p-N2 non-small cell lung cancer
22. p53 status predicts the efficacy of postoperative oral administration of Tegafur for completely resected non-small cell lung cancer
23. Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: Preliminary results from a prospective randomized trial of postoperative adjuvant therapy (Intergroup Trial 0115)